MTP-101-C encapsulated Microbiota
Phase 1Biologic
MTP-101-C encapsulated Microbiota is one of 23 biologic programs targeting Heart Failure. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Brethine
SanofiPreclinical
Amidate
PfizerPreclinical
LCZ696
NovartisPreclinical
Zemplar
AbbViePreclinical
Bystolic
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
Xifaxan
SSalix
Preclinical
Zoloft
VViatris Specialty LLC
Preclinical
Coumadin
AAbbott
Preclinical
Statin
Bristol-Myers SquibbPreclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- MMelana Yuzefpolskaya, MD